Loading patent…
AssigneeOtsuka Pharmaceutical Co., Ltd.
InventorsKim-Hien Dao, Harold Keer, Aram Oganesian
Estimating the term…
Provided according to embodiments of the invention are methods of treating a disorder in a subject in need thereof that include administering to the subject an effective amount of cedazuridine, an effective amount of decitabine, and an effective amount of venetoclax, thereby treating the disorder in the subject. In some embodiments of the invention, the disorder is a hyperproliferative disorder such as a cancer. In some embodiments, the disorder is a hematological cancer such as myelodysplastic syndromes (MDS), myeloproliferative neoplasms (MPN), leukemia (e.g., acute myeloid leukemia), or lymphoma.
A method of treating a disorder in a subject in need thereof, comprising administering to the subject an effective amount of cedazuridine, an effective amount of decitabine, and an effective amount of venetoclax, thereby treating the disorder in the subject.
An oral dosage form comprising cedazuridine, decitabine, and venetoclax, and at least one pharmaceutically acceptable excipient.
20-24. (canceled)
Dependencies are inferred from the claim text.